Pemvidutide (TFA)
Pemvidutide (ALT-801) TFA is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide TFA can be used in non-alcoholic steatohepatitis (NASH) and obesity research[1].
Product Specifications
Product Name Alternative
ALT-801 (TFA)
UNSPSC
12352209
Target
GCGR; GLP Receptor
Related Pathways
GPCR/G Protein
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Purity
98.07
Solubility
H2O : ≥ 50 mg/mL
Smiles
O=C([C@@H](N)CC1=CNC=N1)NC(C)(C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)[C@@H](C)O)=O)CCC(N)=O)=O)CC(C)C)=O)CC(C)C)=O)CC2=CNC3=CC=CC=C23)=O)CCC(N)=O)=O)[C@H](CC)C)=O)CC4=CC=CC=C4)=O)CCC(O)=O)=O)CCCCN5)=O)C)=O)C)=O)CCCCNC([C@@H]6[C@H]([C@@H]([C@H]([C@@H](O6)OCCCCCCCCCCCCCCCCCC(O)=O)O)O)O)=O)=O)CCC5=O)=O)CC(O)=O)=O)CC(C)C)=O)CC7=CC=C(O)C=C7)=O)CCCCN)=O)CO)=O)CC8=CC=C(O)C=C8)=O)CC(O)=O)=O)CO)=O)[C@@H](C)O)=O)CC9=CC=CC=C9)=O)[C@@H](C)O)=O)=O)CCC(N)=O)=O)C.O=C(C(F)(F)F)O.[x]
Molecular Formula
C182H275N39O54.xC2HF3O2
Molecular Weight
3873.35 (free base)
References & Citations
[1]Yabut JM, et al. Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease. Endocr Rev. 2022 Jul 30:bnac018.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K2509408 1.0 µg DNA
TRNAN30 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)
Sign In for Pricing
View Details 